The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month, paving the way ...
South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda. The PD-1 checkpoint inhibitor cancer treatment is fast becoming the ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback